The FDA approved the first RSV vaccine Wednesday, called Arexvy, which is designed to be given as a single shot to adults 60 and over.

The FDA approved the first RSV vaccine Wednesday, called Arexvy, which is designed to be given as a single shot to adults 60 and over.

(NEW YORK) — The U.S. Food and Drug Administration expanded its approval of Moderna’s respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

If the FDA approves the vaccine in August, it will then go to the CDC for final approval and, if approved, could be available as soon as next year.

Zinger Key Points FDA to decide by H1 2026 on expanding GSK's RSV vaccine to at-risk adults aged 18–49. 21 million U.S. adults under 50 have conditions putting them at risk for severe RSV.

The FDA has approved Merck’s Enflonsia, a monoclonal antibody designed to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The approval is based on ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from ...